These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 35292923)

  • 1. Establishment and characterization of NCC-DDLPS5-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.
    Sin Y; Yoshimatsu Y; Noguchi R; Tsuchiya R; Ono T; Akiyama T; Iwata S; Sugaya J; Yoshida A; Kawai A; Kondo T
    Hum Cell; 2022 May; 35(3):936-943. PubMed ID: 35292923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment and characterization of NCC-DDLPS3-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.
    Tsuchiya R; Yoshimatsu Y; Noguchi R; Ono T; Sei A; Takeshita F; Sugaya J; Fukushima S; Yoshida A; Ohtori S; Kawai A; Kondo T
    Hum Cell; 2021 May; 34(3):1008-1018. PubMed ID: 33677797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment and characterization of a novel patient-derived cell line of dedifferentiated liposarcoma, NCC-DDLPS6-C1.
    Yoshimatsu Y; Noguchi R; Sin Y; Tsuchiya R; Ono T; Akiyama T; Nakagawa R; Kamio S; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
    Hum Cell; 2022 Jul; 35(4):1270-1278. PubMed ID: 35604485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment and characterization of NCC-DDLPS1-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.
    Tsuchiya R; Yoshimatsu Y; Noguchi R; Sei A; Takeshita F; Sugaya J; Fukushima S; Yoshida A; Ohtori S; Kawai A; Kondo T
    Hum Cell; 2021 Jan; 34(1):260-270. PubMed ID: 32949334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment and characterization of a novel cell line, NCC-DDLPS2-C1, derived from a patient with dedifferentiated liposarcoma.
    Noguchi R; Yoshimatsu Y; Ono T; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
    Hum Cell; 2021 May; 34(3):990-997. PubMed ID: 33555519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment and Characterization of NCC-DDLPS4-C1: A Novel Patient-Derived Cell Line of Dedifferentiated Liposarcoma.
    Tsuchiya R; Yoshimatsu Y; Noguchi R; Sin Y; Ono T; Akiyama T; Hirose T; Iwata S; Yoshida A; Ohtori S; Kawai A; Kondo T
    J Pers Med; 2021 Oct; 11(11):. PubMed ID: 34834427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment and characterization of NCC-PLPS1-C1, a novel patient-derived cell line of pleomorphic liposarcoma.
    Noguchi R; Yoshimatsu Y; Ono T; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
    Hum Cell; 2021 Mar; 34(2):688-697. PubMed ID: 33205363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Degree of
    Bill KLJ; Seligson ND; Hays JL; Awasthi A; Demoret B; Stets CW; Duggan MC; Bupathi M; Brock GN; Millis SZ; Shakya R; Timmers CD; Wakely PE; Pollock RE; Chen JL
    Oncologist; 2019 Jul; 24(7):989-996. PubMed ID: 31019022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential diagnosis of atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: utility of p16 in combination with MDM2 and CDK4 immunohistochemistry.
    Kammerer-Jacquet SF; Thierry S; Cabillic F; Lannes M; Burtin F; Henno S; Dugay F; Bouzillé G; Rioux-Leclercq N; Belaud-Rotureau MA; Stock N
    Hum Pathol; 2017 Jan; 59():34-40. PubMed ID: 27597521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration.
    Mariño-Enríquez A; Hornick JL; Dal Cin P; Cibas ES; Qian X
    Cancer Cytopathol; 2014 Feb; 122(2):128-37. PubMed ID: 24227706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors.
    Peng T; Zhang P; Liu J; Nguyen T; Bolshakov S; Belousov R; Young ED; Wang X; Brewer K; López-Terrada DH; Oliveira AM; Lazar AJ; Lev D
    Lab Invest; 2011 Mar; 91(3):392-403. PubMed ID: 21060307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology.
    Kim YJ; Kim M; Park HK; Yu DB; Jung K; Song K; Choi YL
    Lab Invest; 2019 Sep; 99(9):1309-1320. PubMed ID: 31160689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The utility of fluorescence in situ hybridization (FISH) in determining DNA damage-inducible transcript 3 (DDIT3) amplification in dedifferentiated liposarcomas - an important diagnostic pitfall.
    Kuczkiewicz-Siemion O; Wiśniewski P; Dansonka-Mieszkowska A; Grabowska-Kierył M; Olszewska K; Goryń T; Prochorec-Sobieszek M; Rutkowski P; Szumera-Ciećkiewicz A
    Pathol Res Pract; 2021 Sep; 225():153555. PubMed ID: 34325315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data.
    Binh MB; Sastre-Garau X; Guillou L; de Pinieux G; Terrier P; Lagacé R; Aurias A; Hostein I; Coindre JM
    Am J Surg Pathol; 2005 Oct; 29(10):1340-7. PubMed ID: 16160477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment and characterization of NCC-PLPS2-C1: a novel cell line of pleomorphic liposarcoma.
    Akiyama T; Yoshimatsu Y; Noguchi R; Sin Y; Osaki J; Adachi Y; Ono T; Tsuchiya R; Sato C; Iwata S; Kojima N; Yoshida A; Ohtori S; Kawai A; Kondo T
    Hum Cell; 2023 Jan; 36(1):468-475. PubMed ID: 36436139
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Casadei L; Calore F; Braggio DA; Zewdu A; Deshmukh AA; Fadda P; Lopez G; Wabitsch M; Song C; Leight JL; Grignol VP; Lev D; Croce CM; Pollock RE
    Cancer Res; 2019 Oct; 79(19):4911-4922. PubMed ID: 31387924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS.
    Schöffski P; Lahmar M; Lucarelli A; Maki RG
    Future Oncol; 2023 Mar; 19(9):621-629. PubMed ID: 36987836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification.
    Cornillie J; Wozniak A; Li H; Gebreyohannes YK; Wellens J; Hompes D; Debiec-Rychter M; Sciot R; Schöffski P
    Clin Transl Oncol; 2020 Apr; 22(4):546-554. PubMed ID: 31201607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.
    Bill KL; Garnett J; Meaux I; Ma X; Creighton CJ; Bolshakov S; Barriere C; Debussche L; Lazar AJ; Prudner BC; Casadei L; Braggio D; Lopez G; Zewdu A; Bid H; Lev D; Pollock RE
    Clin Cancer Res; 2016 Mar; 22(5):1150-60. PubMed ID: 26475335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas?
    Le Guellec S; Chibon F; Ouali M; Perot G; Decouvelaere AV; Robin YM; Larousserie F; Terrier P; Coindre JM; Neuville A
    Am J Surg Pathol; 2014 Mar; 38(3):293-304. PubMed ID: 24525499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.